SCHEMBL514783

SCHEMBL514783

[CH2]OC(=O)Nc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.56
TSHR P16473 2/20 0.56
TP53 P04637 1/20 0.56
EPHX1 P07099 1/20 0.56
EPHX2 P34913 1/20 0.56
CDK9 P50750 1/20 0.56
CLK4 Q9HAZ1 1/20 0.56
NAPRT Q6XQN6 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TGM2 P21980 1/20 0.52
ALDH1A1 P00352 3/20 0.52
GAA P10253 2/20 0.52
HTT P42858 1/20 0.52
RAB9A P51151 4/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
RECQL P46063 1/20 0.49
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092940 0.88 PTPN1 (0.58) SMN1; SMN2ALDH1A1HTTRAB9AKMT2A
SCHEMBL2096940 0.85 HPGD (0.72) SMN1; SMN2TP53EPHX1TGM2ALDH1A1
SCHEMBL2097448 0.83 SLC1A3 (0.51) SMN1; SMN2EPHX2RAB9AKMT2AMEN1
SCHEMBL2094873 0.83 MGLL (0.66) KMT2AMEN1
SCHEMBL2244779 0.81 SMN1; SMN2 (0.61) SMN1; SMN2TSHRTP53EPHX1EPHX2
SCHEMBL8827353 0.81 SMN1; SMN2 (0.61) SMN1; SMN2TSHRTP53EPHX1EPHX2
SCHEMBL9089988 0.80 MAPT (0.54) SMN1; SMN2TSHRALDH1A1GAARAB9A
SCHEMBL2092345 0.79 MGLL (0.51) SMN1; SMN2HSD17B10GAARAB9ANPC1
SCHEMBL282531 0.79 SMN1; SMN2 (0.71) SMN1; SMN2TSHRTP53EPHX1EPHX2
SCHEMBL8612411 0.79 SMN1; SMN2 (0.58) SMN1; SMN2TSHRTP53EPHX1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7081481-B2 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY (US) 2006-07-25 US claimed
US-20040102521-A1 Excitatory amino acid receptor modulators ELI LILLY AND COMPANY 2004-05-27 US claimed
EP-1289940-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-03-12 EP claimed
WO-2001092213-A2 EXCITATORY AMINO ACID RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2001-12-06 WO claimed
US-5563129-A Hydroquinone derivatives and intermediates for production thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-10-08 US claimed
US-5436359-A Hydroquinone derivatives and intermediates for production thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-07-25 US claimed
US-5304658-A Quinone derivatives, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-04-19 US claimed
US-4563446-A ANTICOAGULANT, ANTISCHEMIC TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-01-07 US claimed
US-4343937-A ANTIBIOTICS, BACTERICIDES MERCK & CO., INC. (US) 1982-08-10 US claimed
US-4342869-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-08-03 US claimed
US-4342757-A Cephalosporin antibiotic compositions MERCK & CO., INC. (US) 1982-08-03 US claimed
US-4338437-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US claimed
US-4338438-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US claimed
US-4324890-A ANTIBIOTICS, BACTERICIDES MERCK & CO., INC. (US) 1982-04-13 US claimed
US-4297488-A 7-α-Methoxy cephalosporins MERCK & CO., INC. (US) 1981-10-27 US claimed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
WO-2014184070-A1 MIXTURES OF HALOALKYLSULFONANILIDE DERIVATIVES AND HERBICIDES SYNGENTA LIMITED (GB) 2014-11-20 WO disclosed
US-4150156-A ANTIBIOTICS MERCK & CO., INC. (US) 1979-04-17 US disclosed
US-4123528-A ANTIBIOTICS MERCK & CO., INC. (US) 1978-10-31 US disclosed
US-4086423-A CEPHALOSPORINS, CYCLOADDITION OF GLYCINE DERIVATIVE TO THIAZINE COMPOUND MERCK & CO., INC. (US) 1978-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102521-A1 Excitatory amino acid receptor modulators GRM1, GRM2, GRIN1 SMN1; SMN2 1182/4885TSHR 443/4885TP53 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.